Reaction
Fistula Discharge reporting signals
As of the last recalculation, Fistula Discharge appears in 1,253 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 69.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab-Dyyb | 111 | 69.1 | 69.4 |
| Teduglutide | 25 | 31.4 | 31.5 |
| Metronidazole | 110 | 31.3 | 31.3 |
| Alendronate Sodium | 139 | 25.6 | 25.6 |
| Ciprofloxacin Hydrochloride And Hydrocortisone | 30 | 24.5 | 24.6 |
| Azathioprine | 114 | 23.5 | 23.6 |
| Metronidazole Topical | 61 | 22.3 | 22.3 |
| Risedronate Sodium | 32 | 17.5 | 17.5 |
| Infliximab | 195 | 17.4 | 17.4 |
| Ciprofloxacin | 89 | 17.3 | 17.3 |
| Adalimumab | 472 | 17.2 | 17.2 |
| Ciprofloxacin Hydrochloride | 92 | 16.9 | 16.9 |
| Mesalamine | 54 | 16.6 | 16.7 |
| Chlorhexidine Gluconate | 9 | 16.5 | 16.5 |
| Mercaptopurine | 16 | 15.5 | 15.5 |
| Ciprofolxacin | 59 | 14.3 | 14.3 |
| Ciprofloxacin Tablets | 59 | 14.3 | 14.3 |
| Vedolizumab | 66 | 13.4 | 13.4 |
| Zinc | 19 | 13.0 | 13.0 |
| Zinc Chloride | 19 | 12.9 | 12.9 |
| Ustekinumab | 47 | 7.9 | 7.9 |
| Risankizumab-Rzaa | 27 | 5.6 | 5.6 |